New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - erythromycin ethylsuccinate 93.6 mg/ml equivalent to erythromycin 80 mg/ml (does not include 10% overage) - granules for oral suspension - 400 mg/5ml - active: erythromycin ethylsuccinate 93.6 mg/ml equivalent to erythromycin 80 mg/ml (does not include 10% overage) excipient: aspartame cherry flavour 163837 colloidal silicon dioxide erythrosine propylene glycol alginate sodium benzoate sodium citrate dihydrate sorbitol - streptococcus pyogenes (group a beta-haemolytic streptococcus): upper and lower respiratory tract, skin and soft tissue infections of mild to moderate severity. when oral medication is preferred for treatment of streptococcal pharyngitis and in long term prophylaxis of rheumatic fever, erythromycin is an alternate drug of choice. when oral medication is given, the importance of strict adherence by the patient to the prescribed dosage regimen must be stressed. a therapeutic dose should be administered for at least 10 days. prevention of initial attacks of rheumatic fever: penicillin is considered to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group a beta-haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin-allergic patients. the therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever: penicillin or sulphonamides are considered to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever).

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - erythromycin ethylsuccinate 93.6 mg/ml equivalent to erythromycin 80 mg/ml - granules for oral suspension - 400 mg/5ml - active: erythromycin ethylsuccinate 93.6 mg/ml equivalent to erythromycin 80 mg/ml excipient: aluminium magnesium silicate carmoisine citric acid monohydrate artificial cherry essence pin339465 saccharin sodium sodium citrate dihydrate sodium cyclamate sucrose

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - erythromycin ethylsuccinate 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susce

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - erythromycin 200 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate for oral suspension usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes, streptococcus pneumoniae, or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information.) lower-respiratory tract infections of mild to moderate severity caused by streptococcus pneumonia or streptococcus pyogenes . listeriosis caused by listeria monocytogenes . pertussis (whooping cough) caused by bordetella pertussis . erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. respiratory tract infections due to mycoplasma pneumoniae . skin and skin structure infections of mild to moderate severity caused by streptococcus pyogenes or staphylococcus aureus (resistant staphylococci may emerge during treatment). diphtheria: infections due to corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. erythrasma: in the treatment of infections due to corynebacterium minutissimum . intestinal amebiasis caused by entamoeba histolytica (oral erythromycins only). extraenteric amebiasis requires treatment with other agents. acute pelvic inflammatory disease caused by neisseria gonorrhoeae : as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin. patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. syphilis caused by treponema pallidum : erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. in treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. erythromycins are indicated for the treatment of the following infections caused by chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. when tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to chlamydia trachomatis . when tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by ureaplasma urealyticum . legionnaires' disease caused by legionella pneumophila . although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease. prophylaxis prevention of initial attacks of rheumatic fever penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin-allergic patients.1 the therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever penicillin or sulfonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the american heart association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever).1 erythromycin is contraindicated in patients with known hypersensitivity to this antibiotic. erythromycin is contraindicated in patients taking terfenadine, astemizole, pimozide, or cisapride. (see precautions - drug interactions .) do not use erythromycin concomitantly with hmg coa reductase inhibitors (statins) that are extensively metabolized by cyp 3a4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.

United States - English - NLM (National Library of Medicine)

wilshire pharmaceuticals inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - erythromycin 200 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenza e are not susceptible to the erythromycin concentrati

United States - English - NLM (National Library of Medicine)

azurity pharmaceuticals, inc. (formerly arbor pharmaceuticals) - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - erythromycin 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets, usp and other antibacterial drugs, erythromycin ethylsuccinate tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate tablets, usp are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information.) lower-respiratory tract infections of mild to moderate severity caused by s treptococcus pneumoniae or streptococcus pyogenes . listeriosis caused by listeria monocytogenes . pertussis (whooping cough) caused by bordetella pertussis . erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. respiratory tract infections due to mycoplasma pneumoniae . skin and skin structure infections of mild to moderate severity caused by streptococcus pyogenes or staphylococcus aureus (resistant staphylococci may emerge during treatment). diphtheria: infections due to corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. erythrasma: in the treatment of infections due to corynebacterium minutissimum . intestinal amebiasis caused by entamoeba histolytica (oral erythromycins only). extraenteric amebiasis requires treatment with other agents. acute pelvic inflammatory disease caused by neisseria gonorrhoeae : as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin. patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. syphilis caused by treponema pallidum : erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. in treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. erythromycins are indicated for the treatment of the following infections caused by chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. when tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to chlamydia trachomatis. when tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by ureaplasma urealyticum. legionnaires' disease caused by legionella pneumophila : although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease. penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin-allergic patients. 1 the therapeutic dose should be administered for 10 days. penicillin or sulfonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the american heart association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 1 erythromycin is contraindicated in patients with known hypersensitivity to this antibiotic. erythromycin is contraindicated in patients taking terfenadine, astemizole, pimozide, or cisapride (see precautions - drug interactions ). do not use erythromycin concomitantly with hmg coa reductase inhibitors (statins) that are extensively metabolized by cyp 3a4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d), sulfisoxazole acetyl (unii: wbt5qh3ked) (sulfisoxazole - unii:740t4c525w) - erythromycin ethylsuccinate 200 mg in 5 ml - for treatment of acute otitis media in children that is caused by susceptible strains of haemophilus influenzae . erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension is contraindicated in the following patient populations: use in pregnant women at term, in children less than 2 months of age, and in mothers nursing infants less than 2 months of age is contraindicated because sulfonamides may promote kernicterus in the newborn by displacing bilirubin from plasma proteins. erythromycin is contraindicated in patients taking terfenadine. (see precautions, drug interactions:.)

United States - English - NLM (National Library of Medicine)

rebel distributors corp - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d), sulfisoxazole acetyl (unii: wbt5qh3ked) (sulfisoxazole - unii:740t4c525w) - erythromycin ethylsuccinate 200 mg in 5 ml - for treatment of acute otitis media in children that is caused by susceptible strains of haemophilus influenzae . erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension is contraindicated in the following patient populations: use in pregnant women at term, in children less than 2 months of age, and in mothers nursing infants less than 2 months of age is contraindicated because sulfonamides may promote kernicterus in the newborn by displacing bilirubin from plasma proteins. erythromycin is contraindicated in patients taking terfenadine. (see precautions, drug interactions:.)

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate for oral suspension and other antibacterial drugs, erythromycin ethylsuccinate for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate for oral suspension is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information.) lower-respiratory tract infections of mild to moderate severity caused by streptococcus pneumoniae or streptococcus pyogenes . listeriosis caused by listeria monocytogenes . pertussis (whooping cough) caused by bordetella pertussis . erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. respiratory tract infections due to mycoplasma pneumoniae . skin and skin structure infections of mild to moderate severity caused by streptococcus pyogenes or staphylococcus aureus (resistant staphylococci may emerge during treatment). diphtheria: infections due to corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. erythrasma: in the treatment of infections due to corynebacterium minutissimum . intestinal amebiasis caused by entamoeba histolytica (oral erythromycins only). extraenteric amebiasis requires treatment with other agents. acute pelvic inflammatory disease caused by neisseria gonorrhoeae : as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin. patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. syphilis caused by treponema pallidum : erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. in primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. erythromycins are indicated for the treatment of the following infections caused by chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. when tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to chlamydia trachomatis . when tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by ureaplasma urealyticum . legionnaires' disease caused by legionella pneumophila . although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease.   prophylaxis: prevention of initial attacks of rheumatic fever: penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin-allergic patients.4 the therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever: penicillin or sulfonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the american heart association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever).4 erythromycin is contraindicated in patients with known hypersensitivity to this antibiotic. erythromycin is contraindicated in patients taking terfenadine, astemizole, pimozide, or cisapride. (see precautions - drug interactions . ) do not use erythromycin concomitantly with hmg coa reductase inhibitors (statins) that are extensively metabolized by cyp 3a4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.

United States - English - NLM (National Library of Medicine)

wilshire pharmaceuticals - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrati